Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours

被引:36
作者
Cochran, AJ
Roberts, A
Wen, DR
Huang, RR
Itakura, E
Luo, F
Binder, SW
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA USA
[3] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA
关键词
melanoma; sentinel nodes; microscopy; molecular biology; micrometastases; prognosis;
D O I
10.1080/00313020412331282726
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims: To communicate best practices for sentinel lymph node evaluation and assessment of prognosis for patients with melanoma. Methods: Description and justification of approaches derive from experience with management of more than 2000 melanoma patients evaluated by lymphatic mapping and sentinel node biopsy (LMSNB). Results: Pathologists, by detecting blue dye or carbon particles or alterations in nodal cell populations should attempt to confirm that a node submitted as sentinel is truly sentinel. Pathologists must adequately sample the node by examining multiple tissue sections and determine the presence or absence of metastatic melanoma using sections stained by H&E and immunocytochemistry. Approximately 20% of patients have melanoma in the sentinel node (SN) and accurate evaluation of SN tumour status is the most precise technique for staging clinically localised cutaneous melanoma. The remaining non-sentinel nodes (NSN) in the basin are tumour-free in 67% of patients with melanoma in the SN. Breslow thickness of the primary, the area of tumour in the SN (relative to total nodal area) and density of dendritic leukocytes in the SN paracortex (factors that are combinable in prognostic algorithms) predict metastases in the NSN and the likelihood of recurrence and melanoma-specific death. Conclusions: Careful pathological analysis is essential to determine the presence or absence of metastatic melanoma in sentinel nodes, findings that indicate whether completion lymphadenectomy is required. Quantitative analysis of the primary melanoma and the amount of tumour in the sentinel node, with evaluation of the dendritic cells in that node, provide invaluable information that predicts non-sentinel node tumour status with increased accuracy and the likelihood of future recurrence and death from melanoma. While these activities require considerable effort from pathologists, their clinical impact justifies the increased workload.
引用
收藏
页码:478 / 484
页数:7
相关论文
共 31 条
[11]  
Cochran Alistair J, 2003, Int J Clin Oncol, V8, P139
[12]   The development of optimal pathological assessment of sentinel lymph nodes for melanoma [J].
Cook, MG ;
Green, MA ;
Anderson, B ;
Eggermont, AMM ;
Ruiter, DJ ;
Spatz, A ;
Kissin, MW ;
Powell, BWEM .
JOURNAL OF PATHOLOGY, 2003, 200 (03) :314-319
[13]  
Haigh PI, 2001, CANCER, V92, P535, DOI 10.1002/1097-0142(20010801)92:3<535::AID-CNCR1352>3.0.CO
[14]  
2-3
[15]  
Huang Rong Rong, 2000, Breast J, V6, P225, DOI 10.1046/j.1524-4741.2000.98114.x
[16]   Sentinel lymph node biopsy as an adjunct to management of histologically difficult to diagnose melanocytic lesions: A proposal [J].
Kelley, SW ;
Cockerell, CJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (03) :527-530
[17]   The morphology, immunophenotype and distribution of paracortical dendritic leucocytes in lymph nodes regional to cutaneous melanoma [J].
Lana, AMA ;
Wen, DR ;
Cochran, AJ .
MELANOMA RESEARCH, 2001, 11 (04) :401-410
[18]   Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors [J].
Lohmann, CM ;
Coit, DG ;
Brady, MS ;
Berwick, M ;
Busam, KJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (01) :47-55
[19]   Carbon dye as an adjunct to isosulfan blue dye for sentinel lymph node dissection [J].
Lucci, A ;
Turner, RR ;
Morton, DL .
SURGERY, 1999, 126 (01) :48-53
[20]  
MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392